LL-37 vs KPV for Gut and Skin

Key takeaways

• LL-37 and KPV are sold side by side for gut and skin, but they are opposites in kind: LL-37 is the body's own antimicrobial peptide, which kills microbes and can amplify inflammation; KPV is a synthetic fragment of alpha-MSH whose one established action, in cells and mice, is to damp inflammatory signaling.
• Neither has a human trial for any gut condition. KPV reduced chemically induced colitis in mice in studies from three independent groups. LL-37's gut evidence is mixed and mostly involves the mouse version of the peptide: protective in some mouse models, harmful when bound to bacterial DNA, a complex found raised in people with ulcerative colitis.
• On skin, only LL-37 has human data, and they are topical: in 148 patients with chronic leg ulcers it did no better than placebo overall. It is also implicated in rosacea and psoriasis. KPV has no human skin data at all.
• No study has tested the two together, and their mechanisms point partly in opposite directions. A blend is two unverified research products with no way to tell which caused a reaction.
• Neither can be compounded by a US pharmacy in October 2026. KPV was recommended 8-6-1 by FDA's advisory committee in July 2026 with no rule since; LL-37 is due for committee review by February 2027.

The direct answer: for gut and skin problems, neither LL-37 nor KPV has the human evidence to be a reasonable choice, and they are not interchangeable. KPV is a damper with only animal and cell data; LL-37 is an immune first responder with a few small topical human trials and a documented role in two inflammatory skin diseases. Our LL-37 profile and KPV profile cover each in full; the LL-37 dosage article covers what doses were actually studied.

Side by side

In the gut

KPV has the cleaner story. KPV is carried into intestinal epithelial cells and immune cells by PepT1, the transporter the small intestine uses to absorb dipeptides and tripeptides, which is switched on in the colon lining during inflammatory bowel disease; inside the cell it blocks NF-kappa-B and MAP-kinase signaling at 10 nanomolar, and added to drinking water it reduced two kinds of chemically induced colitis in mice (Dalmasso 2008). A second laboratory reported the same direction in two other colitis models, and colon-targeted nanoparticles carrying KPV worked at far smaller amounts, as our KPV profile details. No human study exists.

LL-37 is murkier, and most of the gut evidence uses the mouse version, CRAMP. Cathelicidin expression rises in the inflamed colon of mice and in mucosal immune cells of patients with inflammatory bowel disease, and mice bred without the gene developed worse chemically induced colitis, which suggests the body's own cathelicidin protects (Koon 2011). A synthetic mouse cathelicidin given into the rectum reduced colitis, restored mucus thickness and lowered fecal bacterial counts in mice (Tai 2007). Against that, LL-37 binds bacterial DNA, and those complexes were raised in the plasma and colon lesions of patients with ulcerative colitis, pushed immune cells toward Th1, Th2 and Th17 responses, increased the permeability of the gut lining in experiments, and, in the mouse version, worsened colitis (Duan 2018). Nobody has given synthetic human LL-37 to a person with a gut disease, by any route, and nobody has shown that an injection under the skin reaches the colon.

So on the gut, KPV has the more consistent animal evidence and the more plausible oral mechanism; LL-37 has animal evidence pointing both ways. Neither is close to a human trial.

On the skin

LL-37 is the only one of the two that has been put on human skin in a controlled trial, and the setting was chronic wounds, not inflammatory skin disease. In 148 patients with hard-to-heal venous leg ulcers, LL-37 at 0.5 or 1.6 mg/mL twice a week for 13 weeks closed 26.5 and 24.7 percent of ulcers against 25.3 percent on placebo, with a benefit seen only in a post hoc subgroup of large wounds (Mahlapuu 2021). For inflamed skin, the evidence runs against it. People with rosacea have abnormally high cathelicidin in their facial skin, processed into abnormal fragments, and those fragments inflamed mouse skin when injected (Yamasaki 2007). In psoriasis, LL-37 binds the body's own DNA and turns it into a trigger for interferon production, a pathway proposed as a driver of the disease (Lande 2007). Someone injecting LL-37 to clear rosacea-prone or psoriatic skin is adding a molecule implicated in both.

KPV has no human skin data. Its skin evidence is a 1989 mouse ear-swelling experiment, human keratinocyte and three-dimensional skin-model cultures, and a rabbit corneal wound study, all summarized in the KPV profile, and no animal model of eczema or psoriasis treated with KPV itself. Its direction, damping inflammatory signaling, is at least the one a person with inflamed skin wants; whether it does that in human skin, at any dose, by any route, is unknown.

Taking them together

People who compare the two often ask about taking both, on the theory that LL-37 clears microbes and KPV calms the inflammation. We found no study of the combination in animals or humans. The mechanisms partly cancel on paper: one peptide suppresses NF-kappa-B, the other activates immune cells and interferon pathways. In practice a combination means two unverified research products, two doses chosen by sellers and no way to attribute a rash, a flare or a fever. The reconstitution calculator can do arithmetic on any vial, but it is built for pharmacy-labeled medications, and neither of these has a label.

What to do instead

For a diagnosed gut disease, start with a gastroenterologist. Ulcerative colitis and Crohn's disease have treatments with randomized trials, chosen by severity and extent, from mesalamine and corticosteroids for flares to immunomodulators, biologics and small-molecule drugs, with the monitoring those drugs need; our KPV versus BPC-157 comparison and gut and inflammation guide set the peptides against them. For rosacea, eczema or psoriasis, start with a dermatologist, who has topical and systemic treatments with trial evidence. For a wound that will not heal, a wound clinic, because chronic wounds usually have a cause no peptide addresses. Do not stop prescribed therapy for a research product, and tell your clinician about anything you add.

Legal status

Neither peptide can be legally compounded in the United States in October 2026. Both came off FDA's Category 2 list on April 15, 2026 after their nominations were withdrawn. On July 23, 2026, FDA's advisory committee voted 8-6-1 to recommend KPV for the permitted list, over the objection of FDA's reviewers (HPM 2026); FDA has not published a rule, so nothing has changed. LL-37 has not been voted on; the committee is due to review it by February 2027. The legal tracker records each step, and a prescription cannot make either one compoundable.

Bottom line

LL-37 and KPV are marketed as a gut-and-skin pair, but they are different kinds of molecule with different problems. KPV is a plausible anti-inflammatory with consistent mouse colitis data and no human study. LL-37 is a real part of human immunity with a few small topical trials, the larger of which was negative, and a documented role in rosacea and psoriasis that makes it a poor choice for inflamed skin. Neither is legally available, neither has been studied in a gut disease in people, and nobody has studied the two together. The treatments that have been tested are a gastroenterologist or dermatologist away.

Frequently asked questions

+−Is LL-37 or KPV better for gut health?

Neither has been tested in a person with any gut condition, so there is no evidence-based winner. KPV has a consistent set of mouse colitis studies from three independent groups and a defined mechanism, a transporter that an inflamed colon switches on. LL-37's gut data are mixed and mostly involve the mouse version of the peptide: the body's own cathelicidin protected mice from colitis, but complexes of LL-37 with bacterial DNA were raised in ulcerative colitis patients and worsened colitis in mice. For ulcerative colitis or Crohn's disease, the treatments with human trials are the ones a gastroenterologist prescribes.

+−Is LL-37 or KPV better for skin?

LL-37 is the only one of the two with human skin data, but those data are topical applications to chronic leg and foot ulcers, and the larger leg-ulcer trial found no benefit over placebo. LL-37 is also implicated in rosacea and psoriasis, so adding it to inflamed skin can work against you. KPV has no human data at all; its skin evidence is a mouse ear-swelling experiment, human skin-cell cultures and a rabbit corneal wound study. For rosacea, eczema or psoriasis, a dermatologist has treatments with randomized trials.

+−Can you take LL-37 and KPV together?

No study has tested the combination in animals or people. The two act in different and partly opposite ways: KPV damps inflammatory signaling inside cells, while LL-37 kills microbes and can amplify immune responses. Combining two unverified research products also means that if you react, nobody can tell which caused it. Neither can be legally compounded in the US in October 2026.

+−What is the difference between LL-37 and KPV?

LL-37 is a 37-amino-acid antimicrobial peptide your own white cells and skin, gut and airway lining make; it kills bacteria, attracts immune cells and helps wounds close. KPV is a synthetic three-amino-acid fragment of alpha-melanocyte-stimulating hormone that keeps the hormone's anti-inflammatory effect without its tanning effect. LL-37 has a few small human trials, all topical or in tumors; KPV has none.

+−Are LL-37 and KPV legal in the US?

Neither is FDA-approved, and no licensed pharmacy may compound either one as of October 2026. Both came off FDA's Category 2 list on April 15, 2026 after their nominations were withdrawn. KPV went further: FDA's advisory committee voted 8-6-1 on July 23, 2026 to recommend it, against FDA staff advice, but no rule has followed. LL-37 is due for committee review by February 2027. Products sold online are research chemicals, and possessing one is not a crime.

+−Is LL-37 anti-inflammatory like KPV?

Not in the same sense. KPV's one established action, in cells and mice, is to switch off NF-kappa-B, the main inflammatory signal. LL-37 neutralizes bacterial endotoxin and helps wounds close, but it also turns the body's own DNA into an immune trigger in psoriasis and produces rosacea-like inflammation when injected into mouse skin. Calling it an anti-inflammatory peptide is not accurate.

+−What should I use instead for colitis, rosacea or psoriasis?

What a specialist prescribes after a diagnosis: for ulcerative colitis or Crohn's disease, mesalamine, corticosteroids for flares, immunomodulators, biologics and small-molecule drugs chosen by severity; for rosacea, eczema or psoriasis, topical treatments and, for moderate-to-severe disease, systemic and biologic drugs with randomized trials. Do not stop or replace prescribed therapy with a research peptide, and tell your clinician about anything you add.

Sources

1. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
2. StudyKoon HW et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology 2011;141:1852-63. (2011)
3. StudyTai EK et al. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood) 2007;232:799-808. (2007)
4. StudyDuan Z et al. Antimicrobial peptide LL-37 forms complex with bacterial DNA to facilitate blood translocation of bacterial DNA and aggravate ulcerative colitis. Sci Bull (Beijing) 2018;63:1364-75. (2018)
5. StudyMahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen 2021;29:938-50. (2021)
6. StudyYamasaki K et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80. (2007)
7. StudyLande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564-9. (2007)
8. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c; FDA reviewers opposed all four). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)